Phase 1 Study Of Pf-03084014 To Evaluate Safety And Pharmacokinetics In Japanese Patients With Advanced Solid Tumors
Latest Information Update: 07 Aug 2015
Price :
$35 *
At a glance
- Drugs Nirogacestat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 03 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 30 Jun 2015 New trial record